{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:33:13Z","timestamp":1775575993722,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"DOI":"10.1186\/s12893-024-02675-x","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:41:11Z","timestamp":1732603271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of qualitative [18F]FDG PET\/CT in predicting clinical outcomes of post-surgical differentiated thyroid cancer patients with elevated thyroglobulin and negative radioiodine whole-body scan"],"prefix":"10.1186","volume":"24","author":[{"given":"Le Ngoc","family":"Ha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Thi","family":"Phuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai Hong","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"5","key":"2675_CR1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","volume":"97","author":"EL Mazzaferri","year":"1994","unstructured":"Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418\u201328.","journal-title":"Am J Med"},{"issue":"1","key":"2675_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12149-022-01799-5","volume":"37","author":"L Yuan","year":"2023","unstructured":"Yuan L, Wang J, Pan L, Feng H, Chen P, Luo J, Xie J, Xiong X, Wu J, Ouyang W. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study. Ann Nucl Med. 2023;37(1):18\u201325.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"2675_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.semnuclmed.2010.10.002","volume":"41","author":"EB Silberstein","year":"2011","unstructured":"Silberstein EB. The Problem of the Patient with Thyroglobulin Elevation but Negative Iodine Scintigraphy: The TENIS Syndrome. Semin Nucl Med. 2011;41(2):113\u201320.","journal-title":"Semin Nucl Med"},{"issue":"9","key":"2675_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.diii.2021.04.004","volume":"102","author":"E Zampella","year":"2021","unstructured":"Zampella E, Klain M, Pace L, Cuocolo A. PET\/CT in the management of differentiated thyroid cancer. Diagn Interv Imaging. 2021;102(9):515\u201323.","journal-title":"Diagn Interv Imaging"},{"issue":"2","key":"2675_CR5","first-page":"221","volume":"48","author":"A Shammas","year":"2007","unstructured":"Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif BB, Joyce JM, Carty SE, Kuffner HA, Avril N. 18F-FDG PET\/CT in Patients with Suspected Recurrent or Metastatic Well-Differentiated Thyroid Cancer. J Nucl Med. 2007;48(2):221\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"2675_CR6","first-page":"12","volume":"4","author":"MH Son","year":"2016","unstructured":"Son MH, Bieu BQ, Ha LN. Value of Dedicated Head and Neck (18)F-FDG PET\/CT Protocol in Detecting Recurrent and Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin Level and Negative (131)I Whole-body Scan. Asia Ocean J Nucl Med Biol. 2016;4(1):12\u20138.","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"2","key":"2675_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.23736\/S1824-4785.22.03364-7","volume":"67","author":"A Rizzo","year":"2023","unstructured":"Rizzo A, Perotti G, Zagaria L, Lanni V, Racca M, Palestini N, Salvatori M. 18F-FDG PET\/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion? Q J Nucl Med Mol Imaging. 2023;67(2):158\u201366.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"8","key":"2675_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/MNM.0b013e32832dcfa7","volume":"30","author":"MJ Dong","year":"2009","unstructured":"Dong MJ, Liu ZF, Zhao K, Ruan LX, Wang GL, Yang SY, Sun F, Luo XG. Value of 18F-FDG-PET\/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun. 2009;30(8):639\u201350.","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2675_CR9","first-page":"e210648","volume":"11","author":"L Giovanella","year":"2022","unstructured":"Giovanella L, Garo ML, Albano D, G\u00f6rges R, Ceriani L. The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis. J Endocr Connect. 2022;11(4):e210648.","journal-title":"J Endocr Connect."},{"issue":"3","key":"2675_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s12020-024-03688-5","volume":"84","author":"P Bellini","year":"2024","unstructured":"Bellini P, Dondi F, Gatta E, Zilioli V, Albano D, Cappelli C, Bertagna F. Prognostic role and characteristics of the indeterminate response in differentiated thyroid cancer: a systematic review. Endocrine. 2024;84(3):812\u201321.","journal-title":"Endocrine"},{"issue":"1","key":"2675_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/EJE-22-0072","volume":"187","author":"CA Lebbink","year":"2022","unstructured":"Lebbink CA, de Vries LH, Borel Rinkes IHM, Braat A, van Leeuwaarde RS, Lodewijk L, van Treijen MJC, Vriens MR, Valk GD, van Santen HM, et al. FDG PET\/CT in differentiated thyroid cancer patients with low thyroglobulin levels. Eur J Endocrinol. 2022;187(1):101\u201310.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2675_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/RLU.0000000000002193","volume":"43","author":"PM Manohar","year":"2018","unstructured":"Manohar PM, Beesley LJ, Bellile EL, Worden FP, Avram AM. Prognostic Value of FDG-PET\/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med. 2018;43(9):641\u20137.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"2675_CR13","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/diagnostics11122189","volume":"11","author":"D Albano","year":"2021","unstructured":"Albano D, Dondi F, Mazzoletti A, Bellini P, Rodella C, Bertagna F. Prognostic Role of 2-[18F]FDG PET\/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET\/CT. Diagnostics. 2021;11(12):2189.","journal-title":"Diagnostics"},{"issue":"11","key":"2675_CR14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s12149-021-01664-x","volume":"35","author":"Y Uchiyama","year":"2021","unstructured":"Uchiyama Y, Hirata K, Watanabe S, Okamoto S, Shiga T, Okada K, Ito YM, Kudo K. Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2021;35(11):1223\u201331.","journal-title":"Ann Nucl Med"},{"key":"2675_CR15","doi-asserted-by":"publisher","first-page":"648658","DOI":"10.3389\/fonc.2021.648658","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Dai H, Li Q, Shen G, Shi L, Tian R. Investigating 18F-FDG PET\/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: a systematic review. Front Oncol. 2021;11:648658.","journal-title":"Front Oncol."},{"issue":"7","key":"2675_CR16","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s00259-009-1306-7","volume":"37","author":"D Vriens","year":"2010","unstructured":"Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging. 2010;37(7):1408\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2675_CR17","first-page":"1430","volume":"11","author":"E Lodi Rizzini","year":"2021","unstructured":"Lodi Rizzini E, Repaci A, Tabacchi E, Zanoni L, Vicennati V, Cavicchi O, Pagotto U, Morganti AG, Fanti S, Monari F. Impact of 18F-FDG PET\/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC). Diagnostics (Basel, Switzerland). 2021;11(8):1430.","journal-title":"Diagnostics (Basel, Switzerland)"},{"issue":"4","key":"2675_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/cancers15041000","volume":"15","author":"F Corica","year":"2023","unstructured":"Corica F, De Feo MS, Stazza ML, Rondini M, Marongiu A, Frantellizzi V, Nuvoli S, Farcomeni A, De Vincentis G, Spanu A. Qualitative and Semiquantitative Parameters of (18)F-FDG-PET\/CT as Predictors of Malignancy in Patients with Solitary Pulmonary Nodule. Cancers. 2023;15(4):1000.","journal-title":"Cancers"},{"issue":"2","key":"2675_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2675_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2018.10.001","volume":"48","author":"SL Asa","year":"2019","unstructured":"Asa SL. The current histologic classification of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):1\u201322.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"2675_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/thy.2017.0102","volume":"27","author":"RM Tuttle","year":"2017","unstructured":"Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid. 2017;27(6):751\u20136.","journal-title":"Thyroid"},{"issue":"1","key":"2675_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"issue":"3","key":"2675_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12149-013-0801-x","volume":"28","author":"E \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir E, Yildirim Poyraz N, Polat SB, Turkolmez S, Ersoy R, Cakir B. Diagnostic value of 18F-FDG PET\/CT in patients with TENIS syndrome: correlation with thyroglobulin levels. Ann Nucl Med. 2014;28(3):241\u20137.","journal-title":"Ann Nucl Med"},{"issue":"8","key":"2675_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","volume":"20","author":"RI Haddad","year":"2022","unstructured":"Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Comprehens Cancer Netwk. 2022;20(8):925\u201351.","journal-title":"J Natl Comprehens Cancer Netwk"},{"issue":"5","key":"2675_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, Smit J. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. Eur Thyroid J. 2019;8(5):227\u201345.","journal-title":"Eur Thyroid J"},{"issue":"8","key":"2675_CR26","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.2967\/jnumed.112.117119","volume":"54","author":"JW Lee","year":"2013","unstructured":"Lee JW, Lee SM, Lee DH. Kim YJJJoNM: Clinical utility of 18F-FDG PET\/CT concurrent with 131I therapy in intermediate\u2013to\u2013high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. Nucl Med. 2013;54(8):1230\u20136.","journal-title":"Nucl Med."},{"issue":"2","key":"2675_CR27","first-page":"221","volume":"48","author":"A Shammas","year":"2007","unstructured":"Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif BB, Joyce JM, Carty SE, Kuffner HA. Avril NJJoNM: 18F-FDG PET\/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48(2):221\u20136.","journal-title":"J Nucl Med."},{"key":"2675_CR28","doi-asserted-by":"publisher","unstructured":"Larg MI, Barbus E, Gabora K, Pestean C, Cheptea M, Piciu D. 18F-FDG PET\/CT IN DIFFERENTIATED THYROID CARCINOMA. Acta Endocrinol (Buchar). 2019;15(2):203\u20138. https:\/\/doi.org\/10.4183\/aeb.2019.203.","DOI":"10.4183\/aeb.2019.203"},{"issue":"10","key":"2675_CR29","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1097\/MNM.0000000000000350","volume":"36","author":"R Ranade","year":"2015","unstructured":"Ranade R, Kand P, Basu S. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome). Nucl Med Commun. 2015;36(10):1014\u201320.","journal-title":"Nucl Med Commun"},{"key":"2675_CR30","doi-asserted-by":"publisher","unstructured":"Vogel J, Sekler J, G\u00fcckel B, Pfannenberg C, Nikolaou K, La Foug\u00e8re C, Dittmann H, Reinert CP. How [18F]FDG-PET\/CT Affects the Management of Patients with Differentiated Thyroid Carcinoma in Clinical Routines. Cancers (Basel). 2024;16(3):588. https:\/\/doi.org\/10.3390\/cancers16030588.","DOI":"10.3390\/cancers16030588"},{"issue":"2","key":"2675_CR31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1210\/jc.2005-1534","volume":"91","author":"RJ Robbins","year":"2006","unstructured":"Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498\u2013505.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2675_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/RLU.0000000000000621","volume":"40","author":"L Pace","year":"2015","unstructured":"Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M. Prognostic role of 18F-FDG PET\/CT in the postoperative evaluation of differentiated thyroid cancer patients. Clin Nucl Med. 2015;40(2):111\u20135.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2675_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1677\/ERC-10-0233","volume":"18","author":"D Deandreis","year":"2011","unstructured":"Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, Lumbroso J, Baudin E, Caillou B, Bidart JM, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18(1):159\u201369.","journal-title":"Endocr Relat Cancer"},{"key":"2675_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11604-011-0572-z","volume":"29","author":"S Nagamachi","year":"2011","unstructured":"Nagamachi S, Wakamatsu H, Kiyohara S, Nishii R, Mizutani Y, Fujita S, Futami S, Arita H, Kuroki M, Nakada H. Comparison of diagnostic and prognostic capabilities of 18 F-FDG-PET\/CT, 131 I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol. 2011;29:413\u201322.","journal-title":"Jpn J Radiol"},{"issue":"5","key":"2675_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/RLU.0000000000000699","volume":"40","author":"FC Gaertner","year":"2015","unstructured":"Gaertner FC, Okamoto S, Shiga T, Ito YM, Uchiyama Y, Manabe O, Hattori N. Tamaki NJCnm: FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med. 2015;40(5):378\u201383.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2675_CR36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1210\/jc.2005-1534","volume":"91","author":"RJ Robbins","year":"2006","unstructured":"Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498\u2013505.","journal-title":"J Clin Endocrinol Metab"},{"key":"2675_CR37","doi-asserted-by":"publisher","unstructured":"Hong CM, Ahn BC, Jeong SY, Lee SW, Lee J. Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake. Nuklearmedizin. 2013;52(4):121\u20139. https:\/\/doi.org\/10.3413\/Nukmed-0541-12-11.","DOI":"10.3413\/Nukmed-0541-12-11"},{"issue":"6","key":"2675_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/RLU.0000000000000780","volume":"40","author":"S Masson-Deshayes","year":"2015","unstructured":"Masson-Deshayes S, Schvartz C, Dalban C, Guendouzen S, Pochart J-M, Dalac A, Fieffe S, Bruna-Muraille C, Dabakuyo-Yonli TS, Papathanassiou D. Prognostic value of 18F-FDG PET\/CT metabolic parameters in metastatic differentiated thyroid cancers. Clin Nucl Med. 2015;40(6):469\u201375.","journal-title":"Clin Nucl Med"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-024-02675-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12893-024-02675-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-024-02675-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:04:02Z","timestamp":1732604642000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-024-02675-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2675"],"URL":"https:\/\/doi.org\/10.1186\/s12893-024-02675-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4249640\/v1","asserted-by":"object"}]},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study protocol was reviewed and approved by the Tumor Board of Hospital 108 (approval No. 338\/Q\u0110-VNC). As the procedures involved were standard of care, the Tumor Board of Hospital 108 agreed to waive the need for written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}